| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Stanley B. Prusiner | Q155380 |
| P2860 | cites work | Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase | Q22254584 |
| Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and betaAPP processing | Q24290265 | ||
| Conversion of alpha-helices into beta-sheets features in the formation of the scrapie prion proteins | Q24564014 | ||
| Prions | Q24633319 | ||
| Elimination of prions by branched polyamines and implications for therapeutics | Q24646752 | ||
| alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies | Q24653247 | ||
| NMR structure of the mouse prion protein domain PrP(121-231) | Q27733163 | ||
| Mutation in the alpha-synuclein gene identified in families with Parkinson's disease | Q27860459 | ||
| Alpha-synuclein in Lewy bodies | Q27860680 | ||
| A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. | Q27860836 | ||
| Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis | Q28131805 | ||
| Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17 | Q28274687 | ||
| Parkinson disease in twins: an etiologic study | Q28296110 | ||
| Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease | Q29614952 | ||
| Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination | Q29614990 | ||
| Eight prion strains have PrP(Sc) molecules with different conformations | Q29617277 | ||
| Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse | Q29619237 | ||
| Solution structure of Syrian hamster prion protein rPrP(90-231). | Q30573700 | ||
| Molecular basis of the neurodegenerative disorders | Q33667722 | ||
| Intracellular APP processing and A beta production in Alzheimer disease | Q33710829 | ||
| Transmission of Creutzfeldt-Jakob disease to a chimpanzee by electrodes contaminated during neurosurgery | Q33732667 | ||
| Alpha-synuclein in Lewy body disease and Alzheimer's disease | Q33750063 | ||
| Expanding our understanding of polyglutamine diseases through mouse models | Q33792953 | ||
| ??? | Q22251293 | ||
| Tau gene mutation in familial progressive subcortical gliosis | Q48236600 | ||
| Biological evidence that scrapie agent has an independent genome | Q48251939 | ||
| Danger of accidental person-to-person transmission of Creutzfeldt-Jakob disease by surgery | Q48313194 | ||
| Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. | Q48338403 | ||
| Frontotemporal dementia and Alzheimer disease: evaluation of cortical atrophy with automated hemispheric surface display generated with MR images. | Q48423008 | ||
| Inherited prion disease with 144 base pair gene insertion. 1. Genealogical and molecular studies. | Q48477334 | ||
| Identification of prion amyloid filaments in scrapie-infected brain. | Q48492399 | ||
| Detection of 14-3-3 protein in the cerebrospinal fluid supports the diagnosis of Creutzfeldt-Jakob disease. | Q48550821 | ||
| Antibodies to a scrapie prion protein. | Q48635549 | ||
| The clinical characteristics of transmissible Creutzfeldt-Jakob disease | Q48700797 | ||
| Analysis of the prion protein gene in thalamic dementia | Q48883631 | ||
| Creutzfeldt-Jakob disease in a recipient of human pituitary-derived gonadotrophin. | Q48924259 | ||
| Prevalence of parkinsonian signs and associated mortality in a community population of older people. | Q51047766 | ||
| Subacute spongiform encephalopathy--a subacute form of encephalopathy attributable to vascular dysfunction (spongiform cerebral atrophy). | Q51306039 | ||
| A 10-year study of the incidence of and factors predicting dementia in Parkinson's disease. | Q52864240 | ||
| Porphyrin and phthalocyanine antiscrapie compounds. | Q54061556 | ||
| Oxidation versus aggregation - how do SOD1 mutants cause ALS? | Q54598711 | ||
| Predicted vCJD mortality in Great Britain | Q56830897 | ||
| Tau protein isoforms, phosphorylation and role in neurodegenerative disorders11These authors contributed equally to this work | Q57897029 | ||
| Deaths from variant Creutzfeldt-Jakob disease | Q59691845 | ||
| Genetics of Parkinson's disease | Q67218920 | ||
| Precise targeting of the pathology of the sialoglycoprotein, PrP, and vacuolar degeneration in mouse scrapie | Q69356290 | ||
| Association between natural scrapie and PrP genotype in a flock of Suffolk sheep in Scotland | Q73047024 | ||
| Creutzfeldt-Jakob disease and related transmissible spongiform encephalopathies | Q77738553 | ||
| Dominant-negative inhibition of prion formation diminished by deletion mutagenesis of the prion protein | Q33803953 | ||
| Molecular genetics of Alzheimer disease | Q33862540 | ||
| Prion protein conformation in a patient with sporadic fatal insomnia | Q33863178 | ||
| Reversing neurodegeneration: a promise unfolds | Q33897927 | ||
| Glutamine repeats and neurodegeneration | Q33938576 | ||
| Narcolepsy: a neurodegenerative disease of the hypocretin system? | Q34072315 | ||
| Some Speculations about Prions, Amyloid, and Alzheimer's Disease | Q34257231 | ||
| Prion propagation in mice expressing human and chimeric PrP transgenes implicates the interaction of cellular PrP with another protein | Q34294957 | ||
| Molecular biology of prion diseases | Q34534878 | ||
| Hashimoto's encephalitis as a differential diagnosis of Creutzfeldt-Jakob disease | Q35449663 | ||
| Mimicking dominant negative inhibition of prion replication through structure-based drug design | Q35759964 | ||
| Mutation in the tau gene in familial multiple system tauopathy with presenile dementia | Q36507684 | ||
| Propagation of prion strains through specific conformers of the prion protein | Q36548578 | ||
| Evidence for protein X binding to a discontinuous epitope on the cellular prion protein during scrapie prion propagation | Q36581272 | ||
| Pathogenic implications of mutations in the tau gene in pallido-ponto-nigral degeneration and related neurodegenerative disorders linked to chromosome 17 | Q36637691 | ||
| Scrapie prion rod formation in vitro requires both detergent extraction and limited proteolysis | Q36682161 | ||
| Compelling transgenetic evidence for transmission of bovine spongiform encephalopathy prions to humans | Q36782262 | ||
| Creutzfeldt-Jakob disease in the United States, 1979-1994: using national mortality data to assess the possible occurrence of variant cases | Q36838448 | ||
| Alzheimer's soluble amyloid beta is a normal component of human urine | Q36865008 | ||
| Creutzfeldt-Jakob Disease: Focus among Libyan Jews in Israel | Q39115314 | ||
| Success and problems of long-term levodopa therapy in Parkinson's disease | Q39419773 | ||
| Epidemiology of Motor-Neuron Diseases | Q39928081 | ||
| Amyotrophic lateral sclerosis and its association with dementia, parkinsonism and other neurological disorders: a review | Q40307172 | ||
| Creutzfeldt-Jakob disease: Patterns of worldwide occurrence and the significance of familial and sporadic clustering | Q41015587 | ||
| Linkage of the Indiana kindred of Gerstmann-Sträussler-Scheinker disease to the prion protein gene | Q41091669 | ||
| To what extent is strain variation evidence for an independent genome in the agent of the transmissible spongiform encephalopathies? | Q41204562 | ||
| Protein fate in neurodegenerative proteinopathies: polyglutamine diseases join the (mis)fold | Q41763638 | ||
| The Lewy body variant of Alzheimer's disease: a clinical and pathologic entity | Q42479244 | ||
| Creutzfeldt-Jakob disease: correlation of MRI and neuropathologic findings | Q42510326 | ||
| Homozygosity for prion protein alleles encoding glutamine-171 renders sheep susceptible to natural scrapie | Q42693681 | ||
| Epidemiology. Tracking the human fallout from 'mad cow disease'. | Q45051119 | ||
| Changes in the localization of brain prion proteins during scrapie infection | Q45219246 | ||
| Creutzfeldt-Jakob disease virus isolations from the Gerstmann-Sträussler syndrome with an analysis of the various forms of amyloid plaque deposition in the virus-induced spongiform encephalopathies | Q45794286 | ||
| Identification of autoantibodies associated with myelin damage in multiple sclerosis | Q46424597 | ||
| Evidence for the conformation of the pathologic isoform of the prion protein enciphering and propagating prion diversity | Q46433690 | ||
| Genetic evidence for the involvement of tau in progressive supranuclear palsy | Q46442862 | ||
| Pathologic conformations of prion proteins | Q46894080 | ||
| Linkage of a prion protein missense variant to Gerstmann-Sträussler syndrome | Q46931937 | ||
| Identification of a gene which controls the incubation period of some strains of scrapie agent in mice | Q47696115 | ||
| Detection of single amyloid beta-protein aggregates in the cerebrospinal fluid of Alzheimer's patients by fluorescence correlation spectroscopy | Q47852588 | ||
| Codon 219 Lys allele of PRNP is not found in sporadic Creutzfeldt-Jakob disease | Q47965426 | ||
| P433 | issue | 20 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | neurodegeneration | Q1755122 |
| prion protein family | Q24724413 | ||
| P304 | page(s) | 1516-1526 | |
| 1516-26 | |||
| P577 | publication date | 2001-05-17 | |
| P1433 | published in | The New England Journal of Medicine | Q582728 |
| P1476 | title | Neurodegenerative Diseases and Prions | |
| Shattuck lecture--neurodegenerative diseases and prions | |||
| P478 | volume | 344 |
| Q48259716 | A 38-year-old man with a 9 month history of neurological and cognitive impairment |
| Q41766591 | A bipolar functionality of Q/N-rich proteins: Lsm4 amyloid causes clearance of yeast prions. |
| Q39945147 | A case of gerstmann-sträussler-scheinker disease |
| Q28681184 | A decade and a half of protein intrinsic disorder: biology still waits for physics |
| Q39024890 | A regulatory role of the Rnq1 nonprion domain for prion propagation and polyglutamine aggregates |
| Q30892024 | A retrospective study of Creutzfeldt-Jakob disease in North of Portugal 1993-2002: demographic, clinical and neuropathological features |
| Q35145020 | A survey of antiprion compounds reveals the prevalence of non-PrP molecular targets |
| Q33933969 | Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease |
| Q48584185 | Advanced glycation end products (AGE) and their receptor (RAGE) in the brain of patients with Creutzfeldt-Jakob disease with prion plaques. |
| Q36005162 | Aggregated proteins in schizophrenia and other chronic mental diseases: DISC1opathies |
| Q35935083 | Aggregation of MBP in chronic demyelination |
| Q34182647 | Allelic origin of protease-sensitive and protease-resistant prion protein isoforms in Gerstmann-Sträussler-Scheinker disease with the P102L mutation |
| Q36913127 | Altered lymphocyte proliferation and innate immune function in scrapie 139A- and ME7-infected mice |
| Q64360547 | Amyloid properties of the yeast cell wall protein Toh1 and its interaction with prion proteins Rnq1 and Sup35 |
| Q34161041 | Amyloidosis and Alzheimer's disease |
| Q41868136 | Amyloids in solid-state nuclear magnetic resonance: potential causes of the usually low resolution |
| Q36601641 | Amyotrophic lateral sclerosis and organ donation: is there risk of disease transmission? |
| Q51249039 | An investigation of potential neurosurgical transmission of Creutzfeldt-Jakob disease: challenges and lessons learned. |
| Q36677402 | An update on pharmacological approaches to neurodegenerative diseases |
| Q35687094 | Anaesthesia in elderly patients with neurodegenerative disorders: special considerations |
| Q82881572 | Analysis of PRNP gene codon 129 polymorphism in the Greek population |
| Q48192397 | Anatamopathological spectrum of tauopathies |
| Q51812016 | Annealing prion protein amyloid fibrils at high temperature results in extension of a proteinase K-resistant core. |
| Q37267798 | Anti-PrP Mab 6D11 suppresses PrP(Sc) replication in prion infected myeloid precursor line FDC-P1/22L and in the lymphoreticular system in vivo |
| Q89484053 | Anti-prion Protein Antibody 6D11 Restores Cellular Proteostasis of Prion Protein Through Disrupting Recycling Propagation of PrPSc and Targeting PrPSc for Lysosomal Degradation |
| Q78727723 | Anti-prion antibodies for prophylaxis following prion exposure in mice |
| Q35030768 | Antiprion compounds that reduce PrP(Sc) levels in dividing and stationary-phase cells. |
| Q35172357 | Apparently sporadic CJD and covert health-care transmissions |
| Q37789524 | Are synucleinopathies prion-like disorders? |
| Q44243235 | Assembly of amyloid protofibrils via critical oligomers--a novel pathway of amyloid formation |
| Q38149753 | Association of heat-shock proteins in various neurodegenerative disorders: is it a master key to open the therapeutic door? |
| Q44688389 | Autocatalytic conversion of recombinant prion proteins displays a species barrier |
| Q47400774 | Beyond the embolus: "do not miss" diffusion abnormalities of ischaemic and non-ischaemic neurological disease |
| Q38579674 | Biochemical aspects of dementias |
| Q51284198 | Biology and Genetics of PrP Prion Strains. |
| Q33567229 | Biology and genetics of prions causing neurodegeneration |
| Q34343507 | Calcium binding promotes prion protein fragment 90-231 conformational change toward a membrane destabilizing and cytotoxic structure. |
| Q90253075 | Case of fatal familial insomnia caused by a d178n mutation with phenotypic similarity to Hashimoto's encephalopathy |
| Q55302403 | Case series of Creutzfeldt-Jakob disease in a third-level hospital in Quito. |
| Q36156685 | Cell division modulates prion accumulation in cultured cells |
| Q38056356 | Cellular mechanisms of protein aggregate propagation |
| Q34815474 | Chaperones and aging: role in neurodegeneration and in other civilizational diseases |
| Q42023365 | Characterization of the amyloid bacterial inclusion bodies of the HET-s fungal prion |
| Q33796040 | Chemical induction of misfolded prion protein conformers in cell culture. |
| Q42576622 | Clinical trials for prion disease: difficult challenges, but hope for the future |
| Q37226238 | Co-existence of distinct prion types enables conformational evolution of human PrPSc by competitive selection |
| Q93332872 | Cognitive Decline: Not Always Alzheimer's Disease |
| Q35522121 | Cognitive aging and Alzheimer's disease |
| Q48392663 | Comparison Between Sporadic and Misdiagnosed Sporadic Creutzfeldt-Jakob Disease: A Report of Two Cases |
| Q92641587 | Complex of EGCG with Cu(II) Suppresses Amyloid Aggregation and Cu(II)-Induced Cytotoxicity of α-Synuclein |
| Q39997860 | Computational and experimental studies on β-sheet breakers targeting Aβ1-40 fibrils. |
| Q43857632 | Computerized morphometric analysis of pathological prion protein deposition in scrapie-infected hamster brain |
| Q39620231 | Conditional modulation of membrane protein expression in cultured cells mediated by prion protein recognition of short phosphorothioate oligodeoxynucleotides. |
| Q35376718 | Conformational transformation and selection of synthetic prion strains |
| Q33595425 | Context dependent neuroprotective properties of prion protein (PrP). |
| Q21090510 | Continuous quinacrine treatment results in the formation of drug-resistant prions |
| Q35539802 | Continuum of prion protein structures enciphers a multitude of prion isolate-specified phenotypes. |
| Q36651921 | Convergent replication of mouse synthetic prion strains |
| Q36640347 | Copper and the prion protein: methods, structures, function, and disease |
| Q44784413 | Copper binding to the neurotoxic peptide PrP106-126: thermodynamic and structural studies |
| Q57629342 | Copper-induced structural propensities of the amyloidogenic region of human prion protein |
| Q42117743 | Creutzfeldt-Jacob Disease: a case report |
| Q54694743 | Creutzfeldt-Jakob disease presenting as refractory nonconvulsive status epilepticus. |
| Q45929842 | Creutzfeldt-Jakob disease with E200K PRNP mutation: a case report and revision of the literature. |
| Q48716012 | Creutzfeldt-Jakob disease: an under-recognized cause of dementia. |
| Q41494811 | Cross-seeding of prions by aggregated α-synuclein leads to transmissible spongiform encephalopathy |
| Q43792763 | Cucumber mosaic virus as the expression system for a potential vaccine against Alzheimer's disease |
| Q36670760 | Decontamination and CJD: the latest guidance |
| Q34939816 | Dementia, the fate of brain? Neuropathological point of view |
| Q37462620 | Development of vaccination approaches for the treatment of neurological diseases |
| Q47375843 | Diagnostic Challenges in Creutzfeldt-Jakob Disease: Case Report |
| Q43072334 | Dichotomous versus palm-type mechanisms of lateral assembly of amyloid fibrils |
| Q44546968 | Dimethyl sulfoxide delays PrP sc accumulation and disease symptoms in prion-infected hamsters |
| Q81749025 | Discordance of motion artifacts on magnetic resonance imaging in Creutzfeldt-Jakob disease: comparison of diffusion-weighted and conventional imaging sequences |
| Q33520644 | Discovery of 2-aminothiazoles as potent antiprion compounds |
| Q33601630 | Discovery of a class of diketopiperazines as antiprion compounds. |
| Q34952164 | Disordered proteins in dementia |
| Q90167845 | Disruption of cellular proteostasis by H1N1 influenza A virus causes α-synuclein aggregation |
| Q43882689 | Distribution of the M129V polymorphism of the prion protein gene in a Turkish population suggests a high risk for Creutzfeldt-Jakob disease |
| Q46584144 | Do prion protein gene polymorphisms induce apoptosis in non-mammals? |
| Q43493602 | Dominant-negative effects in prion diseases: insights from molecular dynamics simulations on mouse prion protein chimeras |
| Q37276740 | Drug resistance confounding prion therapeutics |
| Q46041493 | Dual modulation of ERK1/2 and p38 MAP kinase activities induced by minocycline reverses the neurotoxic effects of the prion protein fragment 90-231. |
| Q33892707 | Dynamic diagnosis of familial prion diseases supports the β2-α2 loop as a universal interference target |
| Q64915784 | Dysregulation of a specific immune-related network of genes biologically defines a subset of schizophrenia. |
| Q30466255 | Early behavioral changes and quantitative analysis of neuropathological features in murine prion disease: stereological analysis in the albino Swiss mice model |
| Q30393556 | Early noninvasive diagnosis of neurodegenerative diseases |
| Q28910222 | Early onset prion disease from octarepeat expansion correlates with copper binding properties |
| Q64969480 | Effects of peptidyl-prolyl isomerase 1 depletion in animal models of prion diseases. |
| Q33560026 | Efficacy of novel acridine derivatives in the inhibition of hPrP90-231 prion protein fragment toxicity |
| Q35869024 | Emerging infections in transfusion medicine |
| Q43527952 | Energy barriers for HET-s prion forming domain amyloid formation |
| Q36559830 | Enhanced correction methods for hydrogen exchange-mass spectrometric studies of amyloid fibrils |
| Q33704994 | Epidemiological mechanisms of genetic resistance to kuru |
| Q36918193 | Evaluation of potential infectivity of Alzheimer and Parkinson disease proteins in recipients of cadaver-derived human growth hormone |
| Q34375245 | Evidence for assembly of prions with left-handed beta-helices into trimers |
| Q52652278 | Exfoliation Syndrome: A Disease of Autophagy and LOXL1 Proteopathy. |
| Q39284075 | Failure of prion protein oxidative folding guides the formation of toxic transmembrane forms. |
| Q28235206 | Folding proteins in fatal ways |
| Q31023317 | From high-throughput cell culture screening to mouse model: identification of new inhibitor classes against prion disease |
| Q35035428 | Fundamentals of prion biology and diseases |
| Q48532612 | Genetic prion disease: the EUROCJD experience. |
| Q33747695 | Genetics and molecular pathogenesis of sporadic and hereditary cerebral amyloid angiopathies |
| Q24294784 | Gerstmann-Sträussler-Scheinker disease amyloid protein polymerizes according to the "dock-and-lock" model |
| Q34476650 | Grass plants bind, retain, uptake, and transport infectious prions |
| Q89629705 | Gyriform restricted diffusion in adults: looking beyond thrombo-occlusions |
| Q46756156 | Heightened incidence of sporadic Creutzfeldt-Jakob disease is associated with a shift in clinicopathological profiles |
| Q57464755 | High prevalence of focal and multi-focal somatic genetic variants in the human brain |
| Q43334768 | High-risk biodegradable waste processing by alkaline hydrolysis. |
| Q36083479 | Human and animal spongiform encephalopathies are autoimmune diseases: a novel theory and its supporting evidence |
| Q54386546 | Human embryonic stem cells rapidly take up and then clear exogenous human and animal prions in vitro. |
| Q35792137 | Human prion disease and relative risk associated with chronic wasting disease |
| Q35778031 | Human prion proteins with pathogenic mutations share common conformational changes resulting in enhanced binding to glycosaminoglycans |
| Q34112488 | Human prion strain selection in transgenic mice |
| Q36325681 | Huntington toxicity in yeast model depends on polyglutamine aggregation mediated by a prion-like protein Rnq1 |
| Q36023181 | Identification of I137M and other mutations that modulate incubation periods for two human prion strains |
| Q44973179 | Identification of distinct N-terminal truncated forms of prion protein in different Creutzfeldt-Jakob disease subtypes. |
| Q46782390 | Identifying the minimal copper- and zinc-binding site sequence in amyloid-beta peptides |
| Q37302816 | Immune-directed gene therapeutic development for Alzheimer's, prion, and Parkinson's diseases |
| Q35747479 | Immunization delays the onset of prion disease in mice. |
| Q48373242 | Immunization with DISC1 protein in an animal model of ADHD influences behavior and excitatory amino acids in prefrontal cortex and striatum. |
| Q34565644 | Immunomodulation for prion and prion-related diseases |
| Q40801758 | Impact of SDS surfactant on the interactions of Cu(2+) ions with the amyloidogenic region of human prion protein. |
| Q39301195 | In Absence of the Cellular Prion Protein, Alterations in Copper Metabolism and Copper-Dependent Oxidase Activity Affect Iron Distribution. |
| Q44455463 | In-situ analysis of cellular poly(ADP-ribose) production in scrapie-infected mouse neuroblastoma cells |
| Q42780553 | Infection as a cause of multiple sclerosis |
| Q74769514 | Infectivity of amyloid diseases |
| Q36436176 | Inhibition of PrP(Sc) formation in scrapie infected N2a cells by 5,7,8-trimethyl-3,4-dihydro-2H-1,4-benzoxazine derivatives. |
| Q34378331 | Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins |
| Q48887100 | Inhibitors of gastric acid secretion increase the risk of prion infection in mice. |
| Q28275860 | Insolubility of disrupted-in-schizophrenia 1 disrupts oligomer-dependent interactions with nuclear distribution element 1 and is associated with sporadic mental disease |
| Q44748154 | Intensity of human prion disease surveillance predicts observed disease incidence |
| Q48498733 | Interaction of prion protein with small highly structured RNAs: detection and characterization of PrP-oligomers. |
| Q35135581 | Intrinsically disordered proteins and their (disordered) proteomes in neurodegenerative disorders |
| Q30375050 | Investigation of the molecular similarity in closely related protein systems: The PrP case study. |
| Q34533430 | Involvement of endogenous retroviruses in prion diseases |
| Q35037725 | Iron and iron/manganese ratio in forage from Icelandic sheep farms: relation to scrapie |
| Q47149313 | Joint Scientific Opinion on any possible epidemiological or molecular association between TSEs in animals and humans |
| Q48540572 | Laminin affects polymerization, depolymerization and neurotoxicity of Abeta peptide. |
| Q48094432 | Left-handed polyproline-II helix revisited: proteins causing proteopathies. |
| Q40091428 | M1 RNA is important for the in-cell solubility of its cognate C5 protein: Implications for RNA-mediated protein folding |
| Q33945003 | Mad cow and other maladies: update on emerging infectious diseases |
| Q35756833 | Memory complaints and dementia |
| Q30826347 | Misassembly of full-length Disrupted-in-Schizophrenia 1 protein is linked to altered dopamine homeostasis and behavioral deficits. |
| Q91994951 | Mitochondrial respiratory chain deficiency correlates with the severity of neuropathology in sporadic Creutzfeldt-Jakob disease |
| Q37965374 | Modulating protein activity and cellular function by methionine residue oxidation |
| Q59130053 | Modulation of Mitochondrial Dynamics in Neurodegenerative Diseases: An Insight Into Prion Diseases |
| Q33777544 | Molecular genealogy tools for white-tailed deer with chronic wasting disease. |
| Q36005158 | Molecular pathogenesis of sporadic prion diseases in man. |
| Q48050089 | More than just tails: intrinsic disorder in histone proteins |
| Q37993988 | Nanopore analysis: An emerging technique for studying the folding and misfolding of proteins |
| Q28212108 | Neurodegenerative disorders of protein aggregation |
| Q34315505 | Neurogenetics: advancing the "next-generation" of brain research |
| Q59126066 | Neuroprogression: the hidden mechanism of depression |
| Q64819927 | Neurotheranostics as personalized medicines |
| Q40547810 | Non-glycosylphosphatidylinositol (GPI)-anchored recombinant prion protein with dominant-negative mutation inhibits PrPSc replication in vitro |
| Q30493642 | Nonpolar substitution at the C-terminus of the prion protein, a mimic of the glycosylphosphatidylinositol anchor, partially impairs amyloid fibril formation |
| Q57033230 | Nosocomial Pneumonia Elicits an Endothelial Proteinopathy: Evidence for a Source of Neurotoxic Amyloids in Critically Ill Patients |
| Q39717764 | Novel antibody derivatives for proteome and high-content analysis |
| Q36203757 | Olfactory transmission of neurotropic viruses |
| Q41906667 | On the intrinsic disorder status of the major players in programmed cell death pathways |
| Q42559957 | Optimization of Arylamides as Novel, Potent and Brain-penetrant Antiprion Lead Compounds |
| Q34188738 | Organ distribution of prion proteins in variant Creutzfeldt-Jakob disease |
| Q35022592 | Oxidative stress, perturbed calcium homeostasis, and immune dysfunction in Alzheimer's disease |
| Q38079791 | Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder? |
| Q26850298 | Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders |
| Q35122315 | Perspectives on prion biology, prion disease pathogenesis, and pharmacologic approaches to treatment |
| Q36806526 | Pharmacokinetics and metabolism of 2-aminothiazoles with antiprion activity in mice |
| Q35915771 | Pharmacologic rescue of conformationally-defective proteins: implications for the treatment of human disease |
| Q39441306 | Phenotyping of tianma-stimulated differentiated rat neuronal b104 cells by quantitative proteomics |
| Q41622472 | Plants-Derived Neuroprotective Agents: Cutting the Cycle of Cell Death through Multiple Mechanisms |
| Q45243075 | Polymerization of proteins into amyloid protofibrils shares common critical oligomeric states but differs in the mechanisms of their formation |
| Q36527273 | Possible role of region 152-156 in the structural duality of a peptide fragment from sheep prion protein. |
| Q44641001 | PrP 106-126 altered PrP mRNA gene expression in mouse microglia BV-2 cells |
| Q34123943 | PrPTSE distribution in a primate model of variant, sporadic, and iatrogenic Creutzfeldt-Jakob disease |
| Q38369450 | Predicting the aggregation propensity of prion sequences |
| Q77477315 | Preparing to treat prions |
| Q45238465 | Prion diseases |
| Q35906120 | Prion diseases--close to effective therapy? |
| Q38264466 | Prion protein and aging |
| Q42107232 | Prion protein and copper cooperatively protect neurons by modulating NMDA receptor through S-nitrosylation. |
| Q28475611 | Prion protein paralog doppel protein interacts with alpha-2-macroglobulin: a plausible mechanism for doppel-mediated neurodegeneration |
| Q35172963 | Prion protein trafficking and the development of neurodegeneration |
| Q47565765 | Prion vaccine: is there hope against CJD? |
| Q35171732 | Prions and the human transmissible spongiform encephalopathies |
| Q34413061 | Prions. |
| Q53730976 | Probing the conformation of the prion protein within a single amyloid fibril using a novel immunoconformational assay. |
| Q33937407 | Pros and cons of a prion-like pathogenesis in Parkinson's disease |
| Q34023019 | Protease-sensitive conformers in broad spectrum of distinct PrPSc structures in sporadic Creutzfeldt-Jakob disease are indicator of progression rate |
| Q37671821 | Protection from cytosolic prion protein toxicity by modulation of protein translocation |
| Q58030632 | Protein Aggregation |
| Q37882078 | Protein aggregate spreading in neurodegenerative diseases: problems and perspectives |
| Q28273600 | Protein aggregation and neurodegenerative disease |
| Q34815754 | Protein aggregation in disease: a role for folding intermediates forming specific multimeric interactions |
| Q37950254 | Protein intrinsic disorder as a flexible armor and a weapon of HIV-1. |
| Q90840565 | Protein misassembly and aggregation as potential convergence points for non-genetic causes of chronic mental illness |
| Q46753498 | Protein misfolding cyclic amplification induces the conversion of recombinant prion protein to PrP oligomers causing neuronal apoptosis |
| Q35790921 | Protein misfolding in neurodegenerative diseases |
| Q34524526 | Protein-misfolding diseases and chaperone-based therapeutic approaches |
| Q35941669 | Proteolytic dysfunction in neurodegenerative disorders |
| Q34376138 | Proteomics of dense core secretory vesicles reveal distinct protein categories for secretion of neuroeffectors for cell-cell communication |
| Q34383788 | Proteopathic tau seeding predicts tauopathy in vivo. |
| Q43288312 | Quantitative reverse-transcription polymerase chain reaction analysis of Alzheimer's-associated genes in mouse scrapie |
| Q39145449 | Recent Progress in Alzheimer's Disease Research, Part 1: Pathology |
| Q45291511 | Reduction of Htt inclusion formation in strains of Saccharomyces cerevisiae deficient in certain DNA repair functions: a statistical analysis of phenotype |
| Q40087612 | Region-specific protein misfolding cyclic amplification reproduces brain tropism of prion strains |
| Q37343754 | Related or not? Development of spontaneous Creutzfeldt-Jakob disease in a patient with chronic, well-controlled HIV: A case report and review of the literature |
| Q77776429 | Risks of bovine spongiform encephalopathy and variant Creutzfeldt-Jakob disease in the United States |
| Q38696076 | Role of HSPA1L as a cellular prion protein stabilizer in tumor progression via HIF-1α/GP78 axis |
| Q37922607 | Role of metal ions in aggregation of intrinsically disordered proteins in neurodegenerative diseases |
| Q36197275 | Role of prion protein aggregation in neurotoxicity |
| Q39661595 | Seeded aggregation and toxicity of {alpha}-synuclein and tau: cellular models of neurodegenerative diseases |
| Q34633462 | Selective re-routing of prion protein to proteasomes and alteration of its vesicular secretion prevent PrP(Sc) formation |
| Q37323826 | Simultaneous effects on parvalbumin-positive interneuron and dopaminergic system development in a transgenic rat model for sporadic schizophrenia |
| Q38139218 | Single-chain fragment variable passive immunotherapies for neurodegenerative diseases |
| Q34491356 | Species-dependent differences in cofactor utilization for formation of the protease-resistant prion protein in vitro |
| Q73093016 | Stability of the prion protein-encoding (PRNP) gene in HeLa cells |
| Q42067591 | Structural dynamics of the ΔE22 (Osaka) familial Alzheimer's disease-linked amyloid β-protein. |
| Q28740431 | Styryl-based and tricyclic compounds as potential anti-prion agents |
| Q34104276 | Successes and challenges in phenotype-based lead discovery for prion diseases |
| Q43057853 | Synthetic prions generated in vitro are similar to a newly identified subpopulation of PrPSc from sporadic Creutzfeldt-Jakob Disease |
| Q27316313 | Synthetic prions with novel strain-specified properties |
| Q36020398 | Targeting intrinsically disordered proteins in neurodegenerative and protein dysfunction diseases: another illustration of the D(2) concept |
| Q45004848 | Targeting prion amyloid deposits in vivo. |
| Q59416680 | Tau and 14-3-3 of genetic and sporadic Creutzfeldt–Jakob disease patients in Israel |
| Q36626384 | Tau phosphorylation, aggregation, and cell toxicity |
| Q92155212 | The Dark Matter of Nutrition: Dietary Signals Beyond Traditional Nutrients |
| Q36222201 | The Effects of Ca2+ Concentration and E200K Mutation on the Aggregation Propensity of PrPC: A Computational Study |
| Q27642560 | The Octapeptide Repeats in Mammalian Prion Protein Constitute a pH-dependent Folding and Aggregation Site |
| Q35545150 | The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy |
| Q30496598 | The efficacy of tetracyclines in peripheral and intracerebral prion infection. |
| Q38139561 | The function of α-synuclein |
| Q46403885 | The impact of binding of macrocyclic metal complexes on amyloid fibrillization of insulin and lysozyme. |
| Q64959034 | The neuropathology of the adult cerebellum. |
| Q36526502 | The peculiar nature of unfolding of the human prion protein |
| Q30485085 | The polybasic N-terminal region of the prion protein controls the physical properties of both the cellular and fibrillar forms of PrP. |
| Q53361326 | The role of copper ions in pathophysiology and fluorescent sensors for the detection thereof. |
| Q36565602 | The role of ubiquitin-protein ligases in neurodegenerative disease |
| Q43068298 | The structural intolerance of the PrP alpha-fold for polar substitution of the helix-3 methionines |
| Q38261710 | The structure of human prions: from biology to structural models-considerations and pitfalls |
| Q38492754 | The transmissible spongiform encephalopathies of livestock |
| Q36872884 | Therapeutic approaches for prion and Alzheimer's diseases |
| Q36420250 | Tissue distribution, biochemical properties, and transmission of mouse type A AApoAII amyloid fibrils |
| Q24289511 | Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples |
| Q38919714 | Transfer of disrupted-in-schizophrenia 1 aggregates between neuronal-like cells occurs in tunnelling nanotubes and is promoted by dopamine |
| Q35064110 | Transfusion medicine for the pediatrician |
| Q34289917 | Transmissible spongiform encephalopathies. |
| Q30385084 | Understanding protein non-folding. |
| Q28261398 | Understanding the role of DISC1 in psychiatric disease and during normal development |
| Q47621954 | Using an epidemiological framework and bovine spongiform encephalopathy investigation questionnaire to investigate suspect bovine spongiform encephalopathy cases: an example from a bovine spongiform encephalopathy case in Ireland in 2015. |
| Q30593594 | Utilizing NMR and EPR spectroscopy to probe the role of copper in prion diseases. |
| Q39266409 | Vacuolar-type H+-ATPase V1A subunit is a molecular partner of Wolfram syndrome 1 (WFS1) protein, which regulates its expression and stability |
| Q44462853 | Variation at the ADAM10 gene locus is not associated with Creutzfeldt-Jakob disease. |
| Q38275791 | Viral capsid assembly as a model for protein aggregation diseases: Active processes catalyzed by cellular assembly machines comprising novel drug targets |
| Q35021431 | What's hot in animal biosafety? |
| Q27314189 | Whole Blood Gene Expression Profiling in Preclinical and Clinical Cattle Infected with Atypical Bovine Spongiform Encephalopathy |
| Q36006298 | Working with transmissible spongiform encephalopathy agents |
| Q46558162 | Zn induced structural aggregation patterns of β-amyloid peptides by first-principle simulations and XAS measurements. |
| Q78066602 | [Crazy cows and human prion diseases] |
| Q50523929 | [PSI(+)] aggregate enlargement in rnq1 nonprion domain mutants, leading to a loss of prion in yeast. |
| Q53322538 | [Transcription factor YY1 participates in activation transcription of the human ribosomal protein L11 gene] |
| Q74296065 | [Variant Creutzfeldt-Jakob disease. Epidemiology, detection, diagnosis and prevention with special reference to minimizing risk of iatrogenic transmission by medical products, especially surgical instruments. Report of the Variant Creutzfeldt-Jakob |
Search more.